

**REMARKS**

Pursuant to phone teleconference with Examiners Robert Morgan and Joseph Thomas on  
5 January 3, 2003, Applicant submits this Supplemental Amendment to Amendment filed on  
November 26, 2002. Claims 1, 8, 21, 23 and 26-28 are amended to clarify the invention,  
specifically as discussed.

No new matter is added; support for amended language is found in the Specification  
10 ("electronic" on page 8, line 18; "processor" on page 4, line 10; "automatic" on page 9, line 6;  
and "nucleotide" on page 21, line 5.)

In view of above, it is respectfully submitted by Applicant that claims are in condition  
for allowance. Reconsideration of rejections is requested. No fee is required. For convenience,  
15 a FAX copy of this paper is transmitted (703-305-7687) to the Examiner .

Respectfully submitted,



Dennis S. Fernandez

Reg. No. 34,160

Date: 1/6/2003

25 Address: Fernandez & Associates, LLP  
P.O. Box D  
Menlo Park, CA 94026-6204  
Phone: (650) 325-4999  
Fax: (650) 325-1203  
30 Email: [iploft@iploft.com](mailto:iploft@iploft.com)

**FAX RECEIVED**

**JAN 06 2003**

**GROUP 3600**

**OFFICIAL**

**"VERSION WITH MARKINGS TO SHOW CHANGES MADE"**

**In the Claims:**

Claims 1, 8, 21, and 26-28 are amended, as follow:

5 *(Please note that un-amended claims are included for convenience.)*

1. *(Twice-Amended)* Automated transaction method comprising the steps of:

determining electronically a bioinformatic value associated with a user; and

transacting via a processor with the user according to the bioinformatic value,

10 wherein the bioinformatic value [may be] is automatically determined when or after the user permits access [effectively] to a voluntarily-selected portion of his or her personal genetic nucleotide profile, such accessible portion being associated or used with evaluating the user transaction via said processor, an other portion of such genetic profile being not voluntarily-selected by the user and thereby inaccessible for evaluating the user transaction.

15 2. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value comprises a likelihood or risk of the user having or developing a genetically-based medical or physiological condition, wherein the transaction step comprises providing the user with an insurance policy to cover the  
20 occurrence of the genetically-based condition.

3. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value comprises a likelihood or risk of the user having or developing a genetically-based mental or emotional condition, wherein the transaction  
25 step comprises providing the user with a service contact in contemplation of the occurrence of the genetically-based condition.

4. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value comprises a likelihood or risk of the user having or  
30 developing a genetically-based condition, wherein the transaction step comprises providing the user with a promotional offer or bid to serve the genetically-based condition.

5. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value comprises a classification of the user according to a user-authorized mask, such mask comprising a subset of a genetic sequence associated with the user.

6. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value comprises a likelihood or risk of the user having or developing a genetically-based condition based on a statistical or actuarial table and a genetic or heredity profile associated with the user.

7. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value is processed for transaction with the user according to a rule set that is applicable to a plurality of users in a temporal or jurisdictional grouping on a non-discriminatory basis.

8. *(Amended)* The method of Claim 1 further comprising the steps of:

determining electronically an other bioinformatic value associated with the user; and modifying the transaction with the user according to the other bioinformatic value.

9. *(Un-amended)* The method of Claim 8 wherein:

the other bioinformatic value comprises an increase or decrease of likelihood or risk of the user having or developing the genetically-based condition.

10. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value is determined by a server in a network, and the bioinformatic value is stored confidentially in a database associated with the server, the server transacting remotely with the user through the network to enable a medical service for the user.

11. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value is associated with an other user, and the transaction according to the bioinformatic value occurs separately with both users on a confidential and non-discriminatory basis.

12. *(Un-amended)* The method of Claim 1 wherein:

the bioinformatic value is authentically generated by a portable user device, the transaction updating a user account, which is accessible by the user device.

21. (*Amended*) The method of Claim 1 wherein:

5 the bioinformatic value or the genetic nucleotide profile is represented in a data structure that may be provided in a modulated electronic signal.

22. (*Un-amended*) The method of Claim 1 wherein:

10 the user transaction comprises a plurality of offers to the user for transacting competitively according to the bioinformatic value.

23. (*Amended*) The method of Claim 1 wherein:

15 the bioinformatic value determination generates an alert or report indicating a fraudulent or identical genetic nucleotide profile or state.

24. (*Un-amended*) The method of Claim 1 wherein:

the bioinformatic value determination generates a discrimination indication or alert when comparing bioinformatic values associated with a plurality of users.

20 25. (*Un-amended*) The method of Claim 1 wherein:

the bioinformatic value is determined using a signal generated electronically by a biometric or bioinformatic sensor for determining a personal genetic sequence of the user.

26. (*Amended*) The method of Claim 1 wherein:

25 the bioinformatic value or the genetic nucleotide profile corresponds effectively with a single nucleotide polymorphism (SNP) associated with the user.

27. (*Amended*) Automated transaction method comprising the steps of:

30 permitting by a user [effective] access to a voluntarily-selected portion of a personal genetic nucleotide profile of the user, such accessible portion being used to determine electronically a bioinformatic value associated with the user, an other portion of such genetic nucleotide profile being not voluntarily-selected by the user and thereby inaccessible for determining the bioinformatic value; and

transacting via a processor by the user according to the determined bioinformatic value.

28. (*Amended*) Automated transaction method comprising the steps of:

determining electronically by a care-giver a bioinformatic value associated with a user,  
the user permitting [effective] access to a voluntarily selected portion of a personal genetic

5 nucleotide profile of the user, such accessible portion being used to determine [a] the  
bioinformatic value associated with the user, an other portion of such genetic nucleotide profile  
being not voluntarily-selected by the user and thereby inaccessible for determining the  
bioinformatic value; and

10 transacting via a processor with the user a healthcare service according to the determined  
bioinformatic value.

15